Citigroup Maintains Buy on Travere Therapeutics, Lowers Price Target to $19

Benzinga · 09/27 18:57
Citigroup analyst Carly Kenselaar maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $23 to $19.